lystn

This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma landed Immuneering a $20 million series A round to develop its pipeline--at the outset of the COVID-19 pandemic. Dr. Zeskind joins us for a candid and instructive discussion on getting creative when the economy isn't exactly booming. 

Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!